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Abstract
Background: An association between gout and renal disease is well-recognised but few studies have examined
whether gout is a risk factor for subsequent chronic kidney disease (CKD). Additionally, the impact of urate-lowering
therapy (ULT) on development of CKD in gout is unclear. The objective of this study was to quantify the risk of CKD
stage ≥ 3 in people with gout and the impact of ULT.
Methods: This was a retrospective cohort study using data from the Clinical Practice Research Datalink (CPRD).
Patients with incident gout were identified from general practice medical records between 1998 and 2016 and
randomly matched 1:1 to patients without a diagnosis of gout based on age, gender, available follow-up time and
practice. Primary outcome was development of CKD stage ≥ 3 based on estimated glomerular filtration rate (eGFR)
or recorded diagnosis. Absolute rates (ARs) and adjusted hazard ratios (HRs) were calculated using Cox regression
models. Risk of developing CKD was assessed among those prescribed ULT within 1 and 3 years of gout diagnosis.
Results: Patients with incident gout (n = 41,446) were matched to patients without gout. Development of CKD
stage ≥ 3 was greater in the exposed group than in the unexposed group (AR 28.6 versus 15.8 per 10,000 person-
years). Gout was associated with an increased risk of incident CKD (adjusted HR 1.78 95% CI 1.70 to 1.85). Those
exposed to ULT had a greater risk of incident CKD, but following adjustment this was attenuated to non-
significance in all analyses (except on 3-year analysis of women (adjusted HR 1.31 95% CI 1.09 to 1.59)).
Conclusions: This study has demonstrated gout to be a risk factor for incident CKD stage ≥ 3. Further research
examining the mechanisms by which gout may increase risk of CKD and whether optimal use of ULT can reduce
the risk or progression of CKD in gout is suggested.
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Background
Gout is the most prevalent inflammatory arthritis, affect-
ing 2.5% of adults in the UK and 3.9% in the USA [1, 2].
Chronic kidney disease (CKD) is also a common problem,
with the global prevalence of CKD stages 3–5 (estimated
glomerular filtration rate (eGFR) < 60 mL/min/1.73m2)
estimated to be 10.6% [3]. An association between gout
and CKD has been recognised for many years [4–6].
CKD can progress to end-stage renal disease (ESRD)
and can lead to premature mortality [7]. The rate of
progression to renal replacement therapy (RRT) or death
over 5 years in patients with CKD stage 3 is 1.3% and
24.3%, respectively, and with stage 4 it is 19.9% and 45.7%,
respectively [8]. In our recent systematic review and
meta-analysis, 24% of people with gout had CKD stage ≥ 3
[9]. The association between hyperuricaemia, gout and
CKD is thought to be bidirectional, with CKD known to
be an independent risk factor for gout [10–13] and gout
potentially predisposing to CKD by a number of mecha-
nisms including hyperuricaemia, chronic inflammation
and drug therapy with non-steroidal anti-inflammatory
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drugs (NSAIDs). In addition, hypertension, diabetes melli-
tus and obesity are highly prevalent in gout [14] and CKD,
and are risk factors for CKD [15]. Our systematic review
identified only two cohort studies investigating the risk of
CKD in people with gout. Although large, both examined
risk of ESRD rather than the earlier stages of CKD and
neither used data from Europe [16, 17]. Better under-
standing of the risk of earlier stages of CKD in people with
gout would help guide screening and the management of
associated comorbidities and could aid the early identifica-
tion or possible prevention of CKD in gout.
Urate-lowering therapy (ULT) should be considered for
all patents with gout, in particular those with recurrent
flares or tophi [18–20]. Data from randomised trials sug-
gests that ULT in patients with CKD can slow the rate of
decline of eGFR and reduce risk of progression to ESRD
[21]. However, these trials were largely conducted in indi-
viduals without gout and the impact of ULT on develop-
ment of CKD in people with gout remains unclear. The
aim of this study was to quantify the risk of developing
CKD stage ≥ 3 among patients with incident gout and as-
sess the impact of ULT on this risk.
Methods
Data source and study population
This retrospective cohort study utilised data from the Clin-
ical Practice Research Datalink (CPRD). The CPRD is a
large database containing anonymised UK primary care
medical records [22]. Approximately 98% of the population
of England and Wales is registered with a general practi-
tioner (GP), who is responsible for the majority of a pa-
tient’s medical care [23]. The CPRD covers more than 7%
of the UK population and is representative of the general
UK population in terms of age and gender distribution
[23]. More than 58% of CPRD practices are linked to hos-
pital episode statistics (HES). HES holds data items includ-
ing admissions, diagnoses and operative procedures for all
patients treated in hospitals in England [24]. The linkage is
performed by a trusted third party based on National
Health Service number, date of birth and gender. As HES
only covers England; practices from Scotland, Wales and
Northern Ireland were excluded from this analysis.
In this cohort study the exposed group consisted of
individuals with a first-ever recorded diagnosis of gout
and these were identified from general practice between
1998 and 2016 using previously published methods
[25]. Ascertainment of gout was based on a medical
(Read) code assigned by the GP. Gout diagnoses have
been validated in the CPRD and have a positive predict-
ive value of 90% [26]. Each patient with gout was
assigned an index date corresponding to the date of
gout diagnosis and randomly matched to one patient
without a gout diagnosis or evidence of ULT, on age (±
5 years), gender, available follow-up time (± 3 years)
and practice. Matching on follow up is a common ap-
proach when using the CPRD as patients with chronic
illness typically have longer follow up compared to
those without, and gout is associated with several co-
morbidities [25], it is a proxy method of minimising the
potential bias this may induce. For both exposed and
unexposed patients, follow up commenced from the
index date. Those with evidence of CKD stage ≥ 3 or
RRT before the index date or < 1 year after the index
date were excluded from the study.
The primary outcome was developing CKD stage ≥ 3
and was based on two consecutive measurements of
eGFR< 60 mL/min/1.73m2 at least 3 months apart. eGFR
was calculated using serum creatinine values recorded in
patients’ medical records using the Chronic Kidney Dis-
ease Epidemiology Collaboration equation [27]. For those
considered to have CKD stage ≥ 3, the date of the first
eGFR measurement was taken as the first occurrence of
CKD. We also identified patients with CKD stage ≥ 3 or
more based on a recorded diagnosis of CKD stages 3–5,
ESRD or having evidence of renal replacement therapy
(RRT (kidney transplant or dialysis)) in their primary or
secondary care medical record.
Covariates
To assess the independent association between gout and
CKD stage ≥ 3, information on various baseline character-
istics was extracted. These included body mass index
(BMI), smoking status, index of multiple deprivation
(IMD), and specific comorbidities. The comorbidities in-
cluded were; myocardial infarction, systemic lupus erythe-
matosus (SLE), rheumatoid arthritis, congestive heart
failure, cerebrovascular disease, peripheral vascular dis-
ease, hospitalisations and treated hypertension or diabetes
mellitus before the index date. Information was extracted
on NSAID use (two or more prescriptions) in the 6
months before gout diagnosis. In addition, baseline serum
uric acid (SUA) level was adjusted for in the analyses
examining risk of CKD associated with ULT prescription.
Finally, for each subject we calculated the visit rate on
unique calendar dates with a medical diagnosis code over
the observation time to estimate how often they visited
their general practitioner. The visit rate was then cate-
gorised into tertiles.
Landmark analysis is routinely used to assess the impact
of treatment where there is a potential lag between disease
occurrence and initiation of therapy [28]. As the timing of
initiation of ULT varies after gout diagnosis, we utilised
landmark analysis to examine the effect of ULT on the risk
of CKD. Landmark analysis deals with the issue of immor-
tal time bias, which biases the results in favour of the
treatment under study by granting a spurious survival ad-
vantage to the treated group [28]. In the case of gout, pa-
tients receiving ULT must have at least survived from
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time of diagnosis to time of treatment whereas no such re-
quirement is necessary for the unexposed group (individ-
uals with gout not receiving ULT). Bias would be
introduced by ignoring this, as ULT exposure status may
be dependent on the length of follow up. In landmark ana-
lysis, a fixed time after the initiation of therapy is selected a
priori for conducting survival analysis [29]. Only those
alive, event-free and contributing data at the landmark
time were included in the analysis. Exposure to ULT was
evaluated between the index date (diagnosis of gout) and
the landmark time, whereas development of CKD stage ≥ 3
was only considered after the landmark time point. Two
landmark points were considered in the analysis (1 and
3 years after diagnosis) based on a previously published
study [30]. Only patients initiated on and prescribed more
than 6 months of ULT were considered to be exposed
(Fig. 1). This was based on previous literature [30] and ex-
pert consensus, as allopurinol is started at a low dose and
increased gradually and it can take several months to escal-
ate the dose sufficiently to lower serum urate to below the
biochemical target level. The duration of ULT was calcu-
lated based on quantity prescribed and numeric daily dose.
Statistical analysis
Absolute rates (ARs) of CKD stage ≥ 3 per 10,000
person-years and 95% confidence intervals (CI) were cal-
culated for the exposed and unexposed groups. These
were stratified by age, gender, IMD and time after diagno-
sis. Hazard ratios (HRs) were modelled using Cox propor-
tional hazards regression adjusting for the stated
confounding factors. Those with missing body mass index
(BMI) status were categorised separately and included in
the analysis, as BMI was assumed not to be missing at
random. Similarly, we compared the risk of CKD stage ≥ 3
among those prescribed ULT within 1 and 3 years after
diagnosis to patients with gout who were not prescribed
ULT. The HRs were additionally adjusted for baseline
serum creatinine and uric acid levels. Baseline serum cre-
atinine and uric acid level was considered before the ULT
exposure or landmark date for those not prescribed ULT.
For those with missing laboratory values, an indicator
variable was included in the regression analysis. All miss-
ing values were imputed using a constant to ensure that
all data were included in the analysis. This study was ap-
proved by the CPRD in-house Independent Scientific Ad-
visory Committee (ISAC) reference number 15_214RA.
Sample size calculations: based on previous literature,
we anticipated at least 30,000 cases of incident gout in
HES-linked CPRD matched to a similar number of unex-
posed individuals [31]. Given the annual incidence of stage
3 CKD is 15% (aged 65–74 years) in the UK, our sample
size provided more than 99% power to detect a HR of 1.5
using Cox proportional hazards model at 5% level of sig-
nificance. For the landmark analysis, assuming that 10% of
patients with gout are treated with ULT within the first
year, we had approximately 82% power to detect a HR of
1.35 between ULT users and non-users, using a Cox pro-
portional hazards model at 5% level of significance.
Results
Patients with incident gout (n = 41,446) were identified
and matched to 41,446 patients without gout. At baseline,
mean participant age was 57 years and 81% were male.
The median duration of follow up was 6 years with a total
of 484,455 person-years of follow up. At baseline, patients
with gout had a higher prevalence of diabetes mellitus,
hypertension, vascular disease and obesity. In addition, pa-
tients with gout attended their GP more frequently and
received more NSAID prescriptions than patients without
gout (Table 1).
During follow up, 6694 patients (16.2%) with gout devel-
oped CKD stage ≥ 3 compared to 3953 (9.5%) patients
without gout (absolute rate 28.6 versus 15.8 per 10,000
person-years respectively). A diagnosis of gout was associ-
ated with increased risk of development of CKD stage ≥3
compared to patients without gout (unadjusted HR 1.79
95% CI 1.72 to 1.86). Adjustment for age, gender, comor-
bidities, deprivation, NSAID use, frequency of hospital ad-
mission and GP attendance, had a minimal effect and the
association remained statistically significant (adjusted HR
1.78 95% CI 1.70 to 1.85) (Table 2).
Fig. 1 Graphical illustration of landmark analysis. ULT, urate-lowering therapy
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In the stratified analyses, for both exposed and unex-
posed patients, the absolute rate of development of CKD
stage ≥ 3 was greater in women and increased with age.
The adjusted HRs remained largely consistent between
genders and across all age groups and IMD quintiles
(Table 2). Risk of development of CKD stage ≥ 3 was
found to be higher within the first 2 years of gout diagno-
sis (adjusted HR 2.20 95% CI 2.07 to 2.36) compared to
6–10 years following diagnosis (adjusted HR 1.45 95% CI
1.29 to 1.63). Figure 2 describes the development of CKD
stage ≥ 3 in patients with gout and patients without gout
during follow up.
In the landmark analysis, patients with gout were ex-
cluded due to either death, developing CKD or transfer
from general practice within 1 year (n = 1962) or
3 years (n = 12,947) of gout diagnosis. Of the remaining
Table 1 Basic characteristics of the study population
Variable Gout Non-gout
Number Percentage Number Percentage
Total number 41,446 41,446
Mean age (SD) 57.2 (13.6) 57.1 (13.7)
Median follow up (IQR) 6.0 (3.3, 9.5) 5.9 (3.2, 9.4)
Male 33,574 81.0 33,574 81.0
Body mass index
Normal 7394 17.8 12,341 29.8
Underweight 349 0.8 681 1.6
Overweight 15,537 37.5 14,760 35.6
Obese 15,311 36.9 8417 20.3
Missing 2855 6.9 5247 12.7
Smoking status
Never/ex-smoker 36,153 87.2 34,406 83.0
Current smoker 5293 12.8 7040 17.0
Comorbidities
Diabetes mellitus 2686 6.5 2417 5.8
Treated hypertension 11,982 28.9 6648 16.0
Rheumatoid arthritis 276 0.7 302 0.7
SLE 25 0.1 24 0.1
Heart failure 1342 3.2 482 1.2
Myocardial infarction 1660 4.0 1166 2.8
Cerebrovascular disease 1537 3.7 1241 3.0
Peripheral vascular disease 901 2.2 670 1.6
Anti-diabetic drugs 1847 4.5 1881 4.5
NSAIDs 5852 14.1 1619 3.9
Previous hospitalisations 11,016 26.6 9129 22.0
GP consultation rates (tertiles)
1 10,375 25.0 17,256 41.6
2 14,609 35.2 13,022 31.4
3 16,462 39.7 11,168 26.9
IMD quintiles
1 (least deprived) 10,526 25.4 10,485 25.3
2 10,220 24.7 10,232 24.7
3 8411 20.3 8330 20.1
4 7034 17.0 7164 17.3
5 (most deprived) 5216 12.6 5206 12.6
SLE systemic lupus erythematosus, NSAID non-steroidal anti-inflammatory drug, GP general practitioner, IMD Index of multiple deprivation
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Table 2 Absolute rate of CKD per 10,000 person-years and hazard ratios
Variable Gout Non-gout Unadjusted Adjusted*
n Rate‡ 95% CI n Rate‡ 95% CI Hazard ratio 95% CI Hazard ratio 95% CI
Overall 6694 28.6 27.9, 29.3 3953 15.8 15.3, 16.3 1.79 1.72, 1.86 1.78 1.70, 1.85
Male 4608 23.6 22.9, 24.3 2681 13.0 12.5, 13.5 1.80 1.71, 1.89 1.78 1.69, 1.87
Female 2086 53.8 51.5, 56.1 1272 28.7 27.1, 30.3 1.82 1.70, 1.95 1.79 1.66, 1.93
Age at index in years
< 55 years 690 5.8 5.4, 6.30 279 2.3 2.1, 2.6 2.52 2.19, 2.89 1.78 1.54, 2.07
55–65 1581 24.6 23.4, 25.8 844 12.3 11.5, 13.2 1.99 1.83, 2.16 1.76 1.61, 1.92
65–75 2506 66.2 63.6, 68.8 1498 33.8 32.1, 35.5 1.91 1.79, 2.04 1.87 1.75, 2.00
> 75 1917 141.0 134.8, 147.5 1332 78.1 74.0, 82.4 1.75 1.63, 1.88 1.71 1.59, 1.84
IMD (quintiles)
1 (least deprived) 1579 25.6 24.3, 26.9 914 13.9 13.0, 14.8 1.81 1.67, 1.97 1.84 1.69, 2.01
2 1689 29.2 27.9, 30.7 1008 16.2 15.2, 17.2 1.78 1.65, 1.92 1.79 1.65, 1.94
3 1439 30.9 29.3, 32.5 831 16.7 15.6, 17.9 1.83 1.68, 1.99 1.77 1.62, 1.94
4 1143 29.4 27.8, 31.2 698 16.6 15.4, 17.8 1.76 1.60, 1.93 1.78 1.61, 1.97
5 (most deprived) 841 29.1 27.2, 31.2 501 16.5 15.1, 18.0 1.76 1.57, 1.96 1.67 1.49, 1.88
CKD chronic kidney disease, IMD index of multiple deprivation
*Adjusted for age, gender, body mass index, smoking status, diabetes mellitus, treated hypertension, rheumatoid arthritis, systemic lupus erythematosus, heart
failure, IMD, myocardial infraction, cerebrovascular disease, peripheral vascular disease, history of hospitalisation, consultation rates, and non-steroidal anti-
inflammatory drug exposure, when not stratified by them, ‡ per 10,000 person-years
Fig. 2 Development of chronic kidney disease (CKD) stage ≥ 3 in patients with gout and patients without gout (non-gout) during follow up
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patients with gout, 4198 (10.6%) in the 1-year landmark
analysis and 4793 (16.8%) in the 3-year landmark analysis
were receiving ULT (Additional file 1: Figure S1).
Those receiving ULT were older, more frequently hyper-
tensive and diabetic and had higher baseline serum urate
levels compared to those unexposed to ULT (Table 3).
Those exposed to at least 6 months of ULT within 1 and
3 years of gout diagnosis had a greater risk of development
of CKD stage ≥ 3, compared to those not exposed (1-year
unadjusted HR 1.47 95% CI 1.35 to 1.59, 3-year unadjusted
HR 1.35 95% CI 1.23 to 1.49). This risk however, following
adjustment, was attenuated to non-significance in all ana-
lyses apart from the 3-year landmark analysis in women
only (adjusted HR 1.31 95% CI 1.09 to 1.59) (Table 4).
Discussion
This retrospective cohort study, set in a large UK primary
care population, compared the risk of developing CKD
stage ≥ 3 in those with gout versus those without gout.
Following adjustment for age, gender, comorbidities,
deprivation, NSAID use, frequency of hospital admission
and GP attendance, patients with gout had 78% increased
Table 3 Basic characteristics of gout cases by ULT exposure with 1 and 3 years after gout diagnosis
Variable 1-Year landmark 3-Year landmark
Exposed
n = 4198
Unexposed
n = 35,286
Exposed
n = 4793
Unexposed
n = 23,706
N % N % N % N %
Mean age (SD) 58.2 (12.8) 56.3 (13.5) 56.1 (12.1) 55.1 (12.9)
Male 3485 83.0 28,809 81.6 4151 86.6 19,526 82.4
Body mass index
Normal 530 12.6 6385 18.1 575 12.0 4335 18.3
Underweight 22 0.5 292 0.8 15 0.3 196 0.8
Overweight 1504 35.8 13,294 37.7 1781 37.2 9036 38.1
Obese 1893 45.1 12,801 36.3 2177 45.4 8581 36.2
Missing 249 5.9 2514 7.1 245 5.1 1558 6.6
Smoking status
Never/ex-smoker 3808 90.7 30,501 86.4 4355 90.9 20,459 86.3
Current smoker 390 9.3 4785 13.6 438 9.1 3247 13.7
Comorbidities
Diabetes mellitus 357 8.5 2114 6.0 338 7.1 1259 5.3
Treated hypertension 1539 36.7 9509 26.9 1625 33.9 5856 24.7
Rheumatoid arthritis 40 1.0 213 0.6 39 0.8 122 0.5
Heart failure 200 4.8 900 2.6 166 3.5 372 1.6
Myocardial infraction 219 5.2 1247 3.5 216 4.5 685 2.9
Cerebrovascular disease 176 4.2 1172 3.3 143 3.0 627 2.6
Peripheral vascular disease 118 2.8 663 1.9 85 1.8 351 1.5
Anti-diabetic drugs 233 5.6 1462 4.1 208 4.3 860 3.6
NSAIDs 1082 25.8 4455 12.6 1143 23.8 2887 12.2
Previous hospitalisations 1256 29.9 8964 25.4 1200 25.0 5392 22.7
IMD quintiles
1 871 20.7 9211 26.1 1089 22.7 6338 26.7
2 1021 24.3 8700 24.7 1178 24.6 5894 24.9
3 889 21.2 7076 20.1 977 20.4 4733 20.0
4 764 18.2 5935 16.8 827 17.3 3915 16.5
5 647 15.4 4332 12.3 717 15.0 2810 11.9
Mean serum urate (SD) μmol/L 478.4 (90.8) 432.2 (98.1) 476.5 (95.7) 427.3 (99.1)
Mean serum creatinine (SD)* μmol/L 89.5 (16.7) 87.2 (16.1) 90.3 (15.2) 86.4 (15.4)
NSAID non-steroidal anti-inflammatory drug, IMD Index of multiple deprivation
*Missing serum creatinine value = 10,335 (1-year landmark), 5872 (3-year landmark), missing serum urate: 15,638 (1-year landmark), 10,176 (3-year landmark)
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risk of development of CKD stage ≥ 3 compared to pa-
tients without gout. Risk of CKD development was highest
in the first 2 years following gout diagnosis. Following ad-
justment patients with gout exposed to at least 6 months
ULT had no increased risk of developing CKD compared
to those not exposed, in all analyses apart from analysis in
women receiving ULT within 3 years of diagnosis.
This study has a number of strengths. Participants were
from primary care where the majority of patients with
gout are managed, thus aiding generalisability. The sample
size was large and the median follow up was 6 years,
which should be sufficient for development and ascertain-
ment of CKD stage ≥ 3. Ascertainment of the primary out-
come required either a clinical diagnostic code or two
consecutive eGFR measurements < 60 mL/min/1.73m2.
Utilising biochemical data and Read codes should aid
completeness compared to using codes alone, as GP cod-
ing of CKD has been shown to capture only 72% of those
with biochemically evident disease [32]. Previous cohort
studies examining gout and renal disease used either rec-
ord linkage or diagnostic codes alone and examined either
the severest form of CKD (ESRD) [16, 17] or “renal dis-
eases” [25], which would include a large number of
heterogenous conditions. This is the first study to the best
of our knowledge to examine risk of earlier stages of CKD
and to use biochemical data, which is an additional
strength. Immortal time bias, which could have resulted in
lower observed risk of CKD associated with ULT expos-
ure, was addressed with the use of landmark analysis,
which is also a strength of this study.
An important caveat is gout ascertainment based on
GP-coded diagnoses alone, risking misclassification bias,
although gout diagnoses have been validated in CPRD and
have a positive predictive value of 90% [26]. Ascertain-
ment bias is a possible limitation of this study as patients
with gout presented more frequently to their GP and hos-
pital and had higher prevalence of hypertension and
diabetes mellitus, which could have prompted more fre-
quent renal function testing. GP consultation rates during
follow up were adjusted for in the statistical analysis but
may not completely address this issue. Furthermore, it
was not possible to account for patient ethnicity or the se-
verity of comorbidities. Regarding ULT prescription data,
prescriptions do not necessarily equate to dispensing of
ULT and it was not possible assess adherence.
In this study, those with CKD stage ≥ 3 or RRT occur-
ring pre-index or within 1 year of gout diagnosis were ex-
cluded. Despite this, the possibility of reverse causation
could still potentially underlie an association between gout
and CKD e.g. undiagnosed or mild renal dysfunction lead-
ing to hyperuricaemia, thus conferring risk of gout devel-
opment, with later progression to CKD [33]. It is possible
that our finding of the risk of CKD development being
highest within 2 years of gout diagnosis reflects this. It is
also of note that nine genetic loci associated with both
CKD and serum urate concentration, with varying direc-
tion of effect, have been identified by genome-wide associ-
ation studies, which could further complicate the
relationship between gout and CKD [34].
The prevalence of CKD stage ≥ 3 in gout was found
to be 24% in our recent systematic review and
meta-analysis [9]. We identified only two other pro-
spective studies examining the risk of CKD associated
with gout. These studies reported an increased risk of
ESRD of 57% [17] and 80% [16], in keeping with our
risk estimate for CKD stage ≥ 3. One study published
subsequent to our systematic review found three times
increased risk of “renal diseases” (defined using Read
codes rather than eGFR) following gout diagnosis but
did not differentiate between acute or chronic forms
[25]. In our study allopurinol accounted for 99% of all
ULT prescriptions. We did not find clear evidence that
ULT exposure influenced the risk of developing CKD.
Risk was greater in those exposed to ULT, but those
Table 4 Absolute rate of CKD by ULT exposure
Variable Exposed Unexposed Unadjusted Adjusted*
n Rate‡ 95% CI n Rate‡ 95% CI Hazard ratio 95% CI Hazard ratio 95% CI
1-Year landmark
Overall 674 34.3 31.8, 37.0 4058 23.3 22.6, 24.0 1.47 1.35, 1.59 1.09 0.99, 1.18
Male 450 26.4 24.1, 28.9 2878 19.8 19.1, 20.5 1.33 1.21, 1.47 1.08 0.98, 1.20
Female 224 86.7 76.1, 98.9 1180 41.0 38.7, 43.4 2.01 1.74, 2.32 1.11 0.96, 1.29
3-Year landmark
Overall 549 26.1 24.0, 28.4 2027 19.3 18.4, 20.1 1.35 1.23, 1.49 1.03 0.94, 1.14
Male 390 20.7 18.8, 22.9 1538 17.5 16.6, 18.4 1.19 1.06, 1.33 0.96 0.85, 1.07
Female 159 71.1 60.9, 83.1 489 28.3 25.9, 31.0 2.43 2.03, 2.90 1.31 1.09, 1.59
CKD chronic kidney disease, ULT urate-lowering therapy
*Adjusted for age, gender, body mass index, smoking status, diabetes mellitus, treated hypertension, rheumatoid arthritis, heart failure, index of multiple
deprivation, myocardial infarction, cerebrovascular disease, peripheral vascular disease, history of hospitalisation, non-steroidal anti-inflammatory drug exposure
and baseline serum creatine and uric acid, when not stratified by them. ‡ per 10,000 person-years
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exposed were older and more frequently had diabetes
mellitus and hypertension and these factors appeared
to explain the ULT-CKD association in our data. In pre-
vious studies examining the association between ULT
and renal disease, benefits were noted to be greatest in
those taking higher doses of ULT [35] or reaching tar-
get SUA levels [36]. It is of note, however, that patients
with gout often remain on lower doses of allopurinol
and the majority do not reach target SUA levels [37,
38]. This study has not explored whether target SUA
levels were reached and our finding of no association
may reflect suboptimal urate-lowering rather than the
true effect of ULT.
Women who develop gout are typically older, have more
comorbidities such as hypertension, diabetes mellitus and
obesity and receive ULT less frequently than men [39].
Possible explanations for our finding of increased risk of
CKD associated with ULT in women in the 3-year analysis
include women prescribed ULT potentially having more
severe gout and therefore possibly conferring greater risk
of CKD, incomplete adjustment for comorbidities or med-
ications or ascertainment bias, as comorbid women taking
allopurinol may have more frequent renal function testing.
It is possible that allopurinol has deleterious effects on
renal function in women with gout but to the best of our
knowledge this has not been found in previous studies.
The finding of increased risk was not replicated in the
1-year analysis, however, suggesting the finding in the
3-year analysis could be related to chance.
Whilst it is not possible to make causal inferences from
this observational study, it is worth considering the poten-
tially plausible mechanisms for the association between
gout and CKD. Renal damage could result from comorbid
hypertension, diabetes mellitus, obesity or use of nonste-
roidal anti-inflammatory drugs. Hyperuricaemia-mediated
endothelial dysfunction has been suggested to lead to re-
novascular disease [40], although Mendelian randomisa-
tion studies have not found an association between urate
and CKD [34]. Inflammation in gout is increasingly recog-
nised to persist in the intercritical period between acute
attacks [41, 42], raising the possibility that inflammatory
mechanisms contribute to increased risk. Activation of the
NLRP3 inflammasome and subsequent production of
interleukin-1β is a key inflammatory process in gout [43].
This is of note as renal NLRP3 expression is significantly
increased in CKD and it has been suggested that this and
interleukin-1β contribute to progression of CKD [44, 45].
We are unable to make comparisons to previous cohort
studies, as they have used different outcome measures
and, as discussed above, the possibility of reverse caus-
ation complicates temporal inferences from this study. As
also noted previously, a number of conditions associated
with gout are also risk factors for CKD and incomplete ad-
justment for these could result in residual confounding.
Conclusion
This study has demonstrated gout to be a risk factor for in-
cident CKD stage ≥ 3, after adjustment for age, gender, co-
morbidities, deprivation, NSAID use, frequency of hospital
admission and GP attendance. In clinical practice, renal
function monitoring is often suboptimal in gout [36] sug-
gesting an area for improvement. Further research examin-
ing the mechanisms by which gout may increase risk of
CKD is suggested, including the role of hyperuricaemia
and possible linked inflammatory processes. Due to high
prevalence of CKD in gout, further research into whether
optimal use of ULT can reduce the risk or progression of
CKD in patients with gout would also be of value.
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